(-)Deprenyl (Selegiline): Past, present and future

Neurobiology

Volumn 8, Issue 2, 2000, Pages 179-199

  Knoll, J ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

( )Deprenyl; Alzheimer's disease; Catecholamine releasing effect; Catecholaminergic activity enhancer (CAE) effect; Parkinson's disease; Selegiline

Indexed keywords

DOPAMINE; LEVODOPA; NORADRENALIN; SELEGILINE;

ALZHEIMER DISEASE; ARTICLE; CATECHOLAMINE NERVE CELL; CATECHOLAMINE RELEASE; CATECHOLAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG MECHANISM; NONHUMAN; NORADRENALIN RELEASE; PARKINSON DISEASE;

AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN CHEMISTRY; HUMANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; SELEGILINE;

EID: 0033770513     PISSN: 12168068     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. The functional anatomy of basal ganglia disorders
2. Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMP)
3. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A long-term study
4. (-)Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathion peroxidase in the striatum of young male rats
5. (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: The sex and age-related differences in the optimal dose in the rat
6. Pargyline and (-)deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
7. Multi-centre trials: U-turns by bandwagons and the patient left by the wayside
8. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B
9. Inhibition by (-)deprenyl of dopamine uptake in rat striatum: A possible correlation between dopamine uptake and acetylcholine release inhibition
10. Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence
11. The possible mechanism of action of (-)deprenyl in Parkinson's disease
12. Selective inhibition of B type monoamine oxidase in the brain: A drug strategy to improve the quality of life in senescence
13. The striatal dopamine dependency of lifespan in male rats. Longevity study with (-)deprenyl
14. The pharmacology of selegiline/(-)deprenyl/
15. Nigrostriatal dopaminergic activity, deprenyl treatment and longevity
16. Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases
17. Memories of my 45 years in research
18. (-)Deprenyl (selegiline) in Parkinson's disease: A pharmacologist's comment
19. Sexual performance and longevity
20. (-)Deprenyl (Selegiline) a catecholaminergic activity enhancer (CAE) substance acting in the brain
21. Some puzzling effects of monoamine oxidase inhibitors
22. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition
23. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity. Rationale for prophylactic (-)deprenyl (selegiline) medication
24. Phenylisopropylmethyl propinylamine (E-250) a new psychic energizer
25. Phenylisopropylmethylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effects of tyramine
26. Long-lasting, true aphrodisiac effect of (-)deprenyl in sexually sluggish old male rats
27. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl
28. The pharmacology of 1-phenyl-2-propylaminopentane (PPAP), a deprenyl-derived new spectrum psychostimulant
29. (-)Deprenyl and (-)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin
30. Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference
31. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential - Transmitter release coupling in the catecholaminergic neurons
32. High performing rats are more sensitive toward catecholaminergic activity enhancer (CAE) compounds than their low performing peers
33. Phenylethylamine and tyramine are mixed-acting sympathomimetic amines in the brain
34. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
35. Sexual activity in the aging male
36. Maintenance on L-(-)deprenyl prolongs life in aged male rats
37. Basal ganglia intrinsic circuits and their role in behavior
38. Selegiline as initial treatment in de novo parkinsonian patiens
39. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Patients taking selegiline may have received more levodopa than necessary
40. Effect of (-)deprenyl on the progression disability in early Parkinson's disease
41. Effect to tocopherol and (-)deprenyl on the progression of disability in early Parkinson's disease
42. Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP patients requiring levodopa
43. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease
44. Treatment with L-deprenyl prolongs life in elderly dogs
45. Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity
46. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
47. Treatment of central nervous system degenerative disorders
48. The effect of (-)deprenyl (selegiline) on the natural history of Parkinson's disease
49. A procedure for measuring neuromelanin in neurocytes by a TV-image analyser
50. Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum
51. + in vivo